Edvince

Stroke damage control

  • CEO: Jan Erik Alenfall
  • First investment year: 2016
  • Fund: South
  • Business sector: Life Science

Edvince develops drugs with the potential to minimize damage to the brain caused by stroke and thereby reduce the risk of lifelong disability. Edvince considers drug candidates that work by keeping the blood vessels in the brain open, thereby allowing brain cells to receive oxygen and nutrients in order to prevent widespread and prolonged cell death in the brain.